The University of Southampton
University of Southampton Institutional Repository

Accelarated immune ageing is associated with COVID-19 disease severity

Accelarated immune ageing is associated with COVID-19 disease severity
Accelarated immune ageing is associated with COVID-19 disease severity
Background: the striking increase in COVID-19 severity in older adults provides a clear example of immunesenescence, the age-related remodelling of the immune system. To better characterise the association between convalescent immunesenescence and acute disease severity, we determined the immune phenotype of COVID-19 survivors and non-infected controls.

Results: we performed detailed immune phenotyping of peripheral blood mononuclear cells isolated from 103 COVID-19 survivors 3-5 months post recovery who were classified as having had severe (n = 56; age 53.12 ± 11.30 years), moderate (n = 32; age 52.28 ± 11.43 years) or mild (n = 15; age 49.67 ± 7.30 years) disease and compared with age and sex-matched healthy adults (n = 59; age 50.49 ± 10.68 years). We assessed a broad range of immune cell phenotypes to generate a composite score, IMM-AGE, to determine the degree of immune senescence. We found increased immunesenescence features in severe COVID-19 survivors compared to controls including: a reduced frequency and number of naïve CD4 and CD8 T cells (p -ve CD57+ve senescent CD4 and CD8 T cells; higher frequency (p +ve senescent NK cells. As a result, the IMM-AGE score was significantly higher in severe COVID-19 survivors than in controls (p 

Conclusions: our analyses reveal a state of enhanced immune ageing in survivors of severe COVID-19 and suggest this could be related to SARS-Cov-2 infection. Our data support the rationale for trials of anti-immune ageing interventions for improving clinical outcomes in these patients with severe disease.
Lord, Janet M.
a1869755-13bf-434e-abe3-723b6288c1f0
Veenith, Tonny
03e20ace-4a8c-48d6-ae09-8f8eccabb54e
Sullivan, Jack
c1bcb85d-6d0e-43ba-a794-4bdc1070bcb2
Sharma-Oates, A
fe933301-d7d2-4f60-85ec-268a8a176825
AG, Richter
edb5b4f0-757f-4898-af1d-5bd631645e87
NJ, Greening
44ef748a-20f5-4ccf-8840-1e2f3e18b7c4
HJC, McAuley
d30efd13-9609-483f-8231-0bd44ab1a919
RA, Evans
efcbb0da-3262-49db-b217-e2dff4773068
Moss, P
c10e3fed-ba2e-43db-8324-b28f507b9dab
SC, Moore
f8ba5cde-18fe-4310-92ad-775407e3c9e4
Turtle, L
b16d4607-b64a-4d83-9fd1-b04876b2345e
Gilani, A
5ab805dd-2cd9-4b4c-9256-7c25978ec2b7
Bajaj, M
811a0044-9443-4f8a-9e9d-9d8c344dc5f9
LV, Wain
ec3bb230-e14a-464e-b3a1-545c3f6bb031
Brightling, C
4d8e776e-c4a2-4a34-a8f0-aadddcf00ee3
Raman, B
7cbeb9a8-17fe-4a2d-8416-738945b667b9
Marks, Michael
91d7c45a-1af5-408a-b966-4c29dae6e8af
Singapuri, A
d9066904-5d50-4565-919b-d82d8e88a5cc
Elneima, O
f63465fa-6af2-4346-809d-248160659e7b
PJM, Openshaw
7db6cafd-8672-4713-8c9a-f1ca89c99a7a
NA, Duggal
ac60a316-0084-4acd-976c-5ae4a4e936c2
Jones, Mark
a6fd492e-058e-4e84-a486-34c6035429c1
ISARIC4C Investigators
PHOSP-COVID Study Collaborative Group
Lord, Janet M.
a1869755-13bf-434e-abe3-723b6288c1f0
Veenith, Tonny
03e20ace-4a8c-48d6-ae09-8f8eccabb54e
Sullivan, Jack
c1bcb85d-6d0e-43ba-a794-4bdc1070bcb2
Sharma-Oates, A
fe933301-d7d2-4f60-85ec-268a8a176825
AG, Richter
edb5b4f0-757f-4898-af1d-5bd631645e87
NJ, Greening
44ef748a-20f5-4ccf-8840-1e2f3e18b7c4
HJC, McAuley
d30efd13-9609-483f-8231-0bd44ab1a919
RA, Evans
efcbb0da-3262-49db-b217-e2dff4773068
Moss, P
c10e3fed-ba2e-43db-8324-b28f507b9dab
SC, Moore
f8ba5cde-18fe-4310-92ad-775407e3c9e4
Turtle, L
b16d4607-b64a-4d83-9fd1-b04876b2345e
Gilani, A
5ab805dd-2cd9-4b4c-9256-7c25978ec2b7
Bajaj, M
811a0044-9443-4f8a-9e9d-9d8c344dc5f9
LV, Wain
ec3bb230-e14a-464e-b3a1-545c3f6bb031
Brightling, C
4d8e776e-c4a2-4a34-a8f0-aadddcf00ee3
Raman, B
7cbeb9a8-17fe-4a2d-8416-738945b667b9
Marks, Michael
91d7c45a-1af5-408a-b966-4c29dae6e8af
Singapuri, A
d9066904-5d50-4565-919b-d82d8e88a5cc
Elneima, O
f63465fa-6af2-4346-809d-248160659e7b
PJM, Openshaw
7db6cafd-8672-4713-8c9a-f1ca89c99a7a
NA, Duggal
ac60a316-0084-4acd-976c-5ae4a4e936c2
Jones, Mark
a6fd492e-058e-4e84-a486-34c6035429c1

Lord, Janet M., Veenith, Tonny and Sullivan, Jack , ISARIC4C Investigators and PHOSP-COVID Study Collaborative Group (2024) Accelarated immune ageing is associated with COVID-19 disease severity. Immunity & ageing, 21. (doi:10.1186/s12979-023-00406-z).

Record type: Article

Abstract

Background: the striking increase in COVID-19 severity in older adults provides a clear example of immunesenescence, the age-related remodelling of the immune system. To better characterise the association between convalescent immunesenescence and acute disease severity, we determined the immune phenotype of COVID-19 survivors and non-infected controls.

Results: we performed detailed immune phenotyping of peripheral blood mononuclear cells isolated from 103 COVID-19 survivors 3-5 months post recovery who were classified as having had severe (n = 56; age 53.12 ± 11.30 years), moderate (n = 32; age 52.28 ± 11.43 years) or mild (n = 15; age 49.67 ± 7.30 years) disease and compared with age and sex-matched healthy adults (n = 59; age 50.49 ± 10.68 years). We assessed a broad range of immune cell phenotypes to generate a composite score, IMM-AGE, to determine the degree of immune senescence. We found increased immunesenescence features in severe COVID-19 survivors compared to controls including: a reduced frequency and number of naïve CD4 and CD8 T cells (p -ve CD57+ve senescent CD4 and CD8 T cells; higher frequency (p +ve senescent NK cells. As a result, the IMM-AGE score was significantly higher in severe COVID-19 survivors than in controls (p 

Conclusions: our analyses reveal a state of enhanced immune ageing in survivors of severe COVID-19 and suggest this could be related to SARS-Cov-2 infection. Our data support the rationale for trials of anti-immune ageing interventions for improving clinical outcomes in these patients with severe disease.

Text
s12979-023-00406-z - Version of Record
Available under License Creative Commons Attribution.
Download (3MB)

More information

e-pub ahead of print date: 11 January 2024
Published date: 11 January 2024

Identifiers

Local EPrints ID: 501212
URI: http://eprints.soton.ac.uk/id/eprint/501212
PURE UUID: 6b84d7ec-8208-45ab-b557-1e0068fe892c
ORCID for Mark Jones: ORCID iD orcid.org/0000-0001-6308-6014

Catalogue record

Date deposited: 27 May 2025 17:33
Last modified: 28 May 2025 01:43

Export record

Altmetrics

Contributors

Author: Janet M. Lord
Author: Tonny Veenith
Author: Jack Sullivan
Author: A Sharma-Oates
Author: Richter AG
Author: Greening NJ
Author: McAuley HJC
Author: Evans RA
Author: P Moss
Author: Moore SC
Author: L Turtle
Author: A Gilani
Author: M Bajaj
Author: Wain LV
Author: C Brightling
Author: B Raman
Author: Michael Marks
Author: A Singapuri
Author: O Elneima
Author: Openshaw PJM
Author: Duggal NA
Author: Mark Jones ORCID iD
Corporate Author: ISARIC4C Investigators
Corporate Author: PHOSP-COVID Study Collaborative Group

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×